DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Retinitis Pigmentosa Overview
- Therapeutics Development
- Pipeline Products for Retinitis Pigmentosa - Overview
- Pipeline Products for Retinitis Pigmentosa - Comparative Analysis
- Retinitis Pigmentosa - Therapeutics under Development by Companies
- Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes
- Retinitis Pigmentosa Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Retinitis Pigmentosa - Products under Development by Companies
- Retinitis Pigmentosa - Products under Investigation by Universities/Institutes
- Retinitis Pigmentosa - Companies Involved in Therapeutics Development
- Acucela Inc.
- Amarantus Bioscience Holdings, Inc.
- Amgen Inc.
- Applied Genetic Technologies Corporation
- Asklepios BioPharmaceutical, Inc.
- Astellas Pharma Inc.
- Caladrius Biosciences, Inc.
- Dompe Farmaceutici S.p.A.
- Genable Technologies Limited
- GenSight Biologics S.A.
- Grupo Ferrer Internacional, S.A.
- ID Pharma Co., Ltd.
- InFlectis BioScience
- International Stem Cell Corporation
- Ionis Pharmaceuticals, Inc.
- M's Science Corporation
- Mimetogen Pharmaceuticals Inc.
- Nanovector s.r.l.
- Orphagen Pharmaceuticals, Inc.
- QLT Inc.
- RegenxBio Inc.
- ReNeuron Group Plc
- SanBio, Inc.
- Shire Plc
- Spark Therapeutics, Inc.
- Staidson (Beijing) Biopharmaceuticals Co., Ltd.
- Sucampo Pharmaceuticals, Inc.
- Sun Pharma Advanced Research Company Ltd.
For more information visit http://www.researchandmarkets.com/research/xkmqkd/retinitis